<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702195</url>
  </required_header>
  <id_info>
    <org_study_id>P06054</org_study_id>
    <secondary_id>38817</secondary_id>
    <nct_id>NCT00702195</nct_id>
  </id_info>
  <brief_title>Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)</brief_title>
  <official_title>Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials for the Development of Org 36286 (Corifollitropin Alfa).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial was to evaluate whether Org 36286 treatment in any Phase IIa
      clinical development trial of Org 36286 for OI or COH in assisted reproductive treatment
      programs was safe for pregnant subjects and their offspring. Data from subjects who
      participated in Trials 38805 and 38807 and became pregnant were evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open prospective follow-up trial to monitor pregnancy, delivery, and neonatal
      outcome of women who became pregnant during any Phase IIa clinical trial of Org 36286 for OI
      or COH for IVF. For this trial, no study specific assessments were required, but information
      obtained in standard practice was used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2002</start_date>
  <completion_date type="Actual">September 15, 2003</completion_date>
  <primary_completion_date type="Actual">September 15, 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy status at 20 weeks of gestation; Take-home baby rate</measure>
    <time_frame>one pregnancy period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy follow-up; Delivery follow-up; Neonatal outcome; Infant follow-up; Congenital Malformations and Chromosomal Abnormalities</measure>
    <time_frame>one pregnancy period</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">29</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <description>all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group 2</arm_group_label>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group 3</arm_group_label>
    <description>all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group 4</arm_group_label>
    <description>150 IU Puregon®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Org 36286 (corifollitropin alfa)</intervention_name>
    <description>single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807</description>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <arm_group_label>Experimental Group 3</arm_group_label>
    <other_name>corifollitropin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of placebo (administered under protocol 38805)</description>
    <arm_group_label>Experimental Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recFSH</intervention_name>
    <description>150 IU recFSH daily (reference group administered under protocol 38807)</description>
    <arm_group_label>Experimental Group 4</arm_group_label>
    <other_name>follitropin beta</other_name>
    <other_name>Puregon®</other_name>
    <other_name>Follistim®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All women who became pregnant during Trials 38805 or 38807 were enrolled in Trial 38817
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects taking part in any clinical development trial of Org 36286 for OI or COH for
             IVF in Phase IIa;

          -  Ongoing pregnancy confirmed by ultrasonography (USS) at or beyond 12 weeks of
             gestation;

          -  Able and willing to give written informed consent.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal outcome</keyword>
  <keyword>Congenital malformations</keyword>
  <keyword>In-Vitro Fertilization</keyword>
  <keyword>Controlled ovarian stimulation</keyword>
  <keyword>Follow-up</keyword>
  <keyword>Ovulation Induction</keyword>
  <keyword>Neonates</keyword>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

